Levels of bone marrow microvessel density are crucial for evaluating the status of acute myeloid leukemia

Song,Yanqiu; Tan,Yan; Liu,Libo; Wang,Qian; Zhu,Jing; Liu,Min

doi:10.3892/ol.2015.3209

Levels of bone marrow microvessel density are crucial for evaluating the status of acute myeloid leukemia

Authors:
- Yanqiu Song
- Yan Tan
- Libo Liu
- Qian Wang
- Jing Zhu
- Min Liu
View Affiliations

Affiliations: Cancer Center, The First Hospital, Jilin University, Changchun, Jilin 130021, P.R. China, Department of Oncology, Jilin Province People's Hospital, Changchun, Jilin 130021, P.R. China, Department of Hematology, The Fourth Hospital, Jilin University, Changchun, Jilin 130021, P.R. China, Department of Oncology, Jilin Cancer Hospital, Changchun, Jilin 130021, P.R. China, Department of Radiation Oncology, The First Hospital, Jilin University, Changchun, Jilin 130021, P.R. China
Published online on: May 14, 2015 https://doi.org/10.3892/ol.2015.3209
Pages: 211-215
Copyright: © Song et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to determine the efficacy of bone marrow microvessel density (BM-MVD) in the evaluation of the status of acute myeloid leukemia (AML). The levels of serum and bone marrow vascular endothelial growth factor (VEGF), and BM‑MVD in 28 patients with AML, 10 patients with non‑Hodgkin's lymphoma, 10 patients with anemia and 14 patients with AML that achieved complete remission for six months (AML-DFS) subsequent to chemotherapy were determined by ELISA and immunohistochemistry. The levels of serum VEGF in patients with hematological disorders were significantly increased compared with the levels in the healthy controls. The levels of BM VEGF and BM‑MVD in AML patients were significantly higher compared with the levels in the patients with non‑Hodgkin's lymphoma or anemia. Following chemotherapy, the levels of serum VEGF significantly increased and the levels of BM VEGF decreased in the AML patients, regardless of their therapeutic responses, compared with the levels prior to treatment. By contrast, the levels of BM‑MVD in the AML patients were significantly reduced in the patients that completely recovered from AML (AML‑DFS group), compared with those in other groups. The present data indicate that the levels of BM‑MVD are valuable for evaluating the status of AML.

View Figures

View References

1	Ellis LM, Rosen L and Gordon MS: Overview of anti-VEGF therapy and angiogenesis. Part 1 Angiogenesis inhibition in solid tumor malignancies. Clin Adv Hematol Oncol. 4 (Suppl):1–10. 2006.PubMed/NCBI
2	Hurwitz HI, Fehrenbacher L, Hainsworth JD, Heim W, Berlin J, Holmgren E, Hambleton J, Novotny WF and Kabbinavar F: Bevacizumab in combination with fluorouracil and leucovorin: An active regimen for first-line metastatic colorectal cancer. J Clin Oncol. 23:3502–3508. 2005. View Article : Google Scholar : PubMed/NCBI
3	Connolly DT: Vascular permeability factor: A unique regulator of blood vessel function. J Cell Biochem. 47:219–223. 1991. View Article : Google Scholar : PubMed/NCBI
4	Howlader N, Noone AM, Krapcho M, et al: SEER Cancer Statistics Review, 1975–2009 (vintage 2009 populations). National Cancer Institute; Bethesda, MD: 2012
5	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
6	Dores GM, Devesa SS, Curtis RE, Linet MS and Morton LM: Acute leukemia incidence and patient survival among children and adults in the United States, 2001–2007. Blood. 119:34–43. 2012. View Article : Google Scholar : PubMed/NCBI
7	Moorman AV, Chilton L, Wilkinson J, Ensor HM, Bown N and Proctor SJ: A population-based cytogenetic study of adults with acute lymphoblastic leukemia. Blood. 115:206–214. 2010. View Article : Google Scholar : PubMed/NCBI
8	Patel JP, Gönen M, Figueroa ME, Fernandez H, Sun Z, Racevskis J, Van Vlierberghe P, Dolgalev I, Thomas S, Aminova O, et al: Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. 366:1079–1089. 2012. View Article : Google Scholar : PubMed/NCBI
9	Ghosh K, Swaminathan S, Madkaikar M, Gupta M, Kerketta L and Vundinti B: FLT3 and NPM1 mutations in a cohort of AML patients and detection of a novel mutation in tyrosine kinase domain of FLT3 gene from Western India. Ann Hematol. 91:1703–1712. 2012. View Article : Google Scholar : PubMed/NCBI
10	Hung CH, Yang SN, Kuo PL, Chu YT, Chang HW, Wei WJ, Huang SK and Jong YJ: Modulation of cytokine expression in human myeloid dendritic cells by environmental endocrine-disrupting chemicals involves epigenetic regulation. Environ Health Perspect. 118:67–72. 2010.PubMed/NCBI
11	Todorovic M, Radisavljevic Z, Balint B, Andjelic B, Todorovic V, Jovanovic MP and Mihaljevic B: Increased angiogenesis-associated poor outcome in acute lymphoblastic leukemia: A single center study. Appl Immunohistochem Mol Morphol. 20:488–493. 2012. View Article : Google Scholar : PubMed/NCBI
12	Connolly DT, Heuvelman DM, Nelson R, Olander JV, Eppley BL, Delfino JJ, Siegel NR, Leimgruber RM and Feder J: Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J Clin Invest. 84:1470–1478. 1989. View Article : Google Scholar : PubMed/NCBI
13	Hahn D, Simak R, Steiner GE, Handisurya A, Susani M and Marberger M: Expression of the VEGF-receptor Flt-1 in benign, premalignant and malignant prostate tissues. J Urol. 164:506–510. 2000. View Article : Google Scholar : PubMed/NCBI
14	Fontanella C, Ongaro E, Bolzonello S, Guardascione M, Fasola G and Aprile G: Clinical advances in the development of novel VEGFR2 inhibitors. Ann Transl Med. 2:1232014.PubMed/NCBI
15	Sahni A and Francis CW: Vascular endothelial growth factor binds to fibrinogen and fibrin and stimulates endothelial cell proliferation. Blood. 96:3772–3778. 2000.PubMed/NCBI
16	Keyhani A, Jendiroba DB and Freireich EJ: Angiogenesis and leukemia. Leuk Res. 25:639–645. 2001. View Article : Google Scholar : PubMed/NCBI
17	Shalaby F, Rossant J, Yamaguchi TP, Gertsenstein M, Wu XF, Breitman ML and Schuh AC: Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature. 376:62–66. 1995. View Article : Google Scholar : PubMed/NCBI
18	Song GL and Han ZC: Malignant hematologic disease and angiogenesis. Zhonghua Xue Ye Xue Za Zhi. 23:217–219. 2002.(In Chinese).
19	Kampen KR, Ter Elst A and de Bont ES: Vascular endothelial growth factor signaling in acute myeloid leukemia. Cell Mol Life Sci. 70:1307–1317. 2013. View Article : Google Scholar : PubMed/NCBI
20	Kvasnicka HM and Thiele J: Bone marrow angiogenesis: Methods of quantification and changes evolving in chronic myeloproliferative disorders. Histol Histopathol. 19:1245–1260. 2004.PubMed/NCBI
21	Kuzu I, Beksac M, Arat M, Celebi H, Elhan AH and Erekul S: Bone marrow microvessel density (MVD) in adult acute myeloid leukemia (AML): Therapy induced changes and effects on survival. Leuk Lymphoma. 45:1185–1190. 2004. View Article : Google Scholar : PubMed/NCBI
22	Du W, Hattori Y, Hashiguchi A, Kondoh K, Hozumi N, Ikeda Y, Sakamoto M, Hata J and Yamada T: Tumor angiogenesis in the bone marrow of multiple myeloma patients and its alteration by thalidomide treatment. Pathol Int. 54:285–294. 2004. View Article : Google Scholar : PubMed/NCBI
23	Perez-Atayde AR, Sallan SE, Tedrow U, Connors S, Allred E and Folkman J: Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am J Pathol. 150:815–821. 1997.PubMed/NCBI
24	Padró T, Ruiz S, Bieker R, Bürger H, Steins M, Kienast J, Büchner T, Berdel WE and Mesters RM: Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood. 95:2637–2644. 2000.PubMed/NCBI
25	Harris NL, Jaffe ES, Diebold J, Flandrin G, et al: World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol. 17:3835–3849. 1999.PubMed/NCBI
26	Mangi MH and Newland AC: Angiogenesis and angiogenic mediators in hematological malignancies. Br J Hematol. 111:43–51. 2000. View Article : Google Scholar
27	Swerdlow SH, Campo E, Harris NL, et al: WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues. 4th. IARC Press; Lyon, France: 2008
28	Kini AR, Peterson LA, Tallman MS and Lingen MW: Angiogenesis in acute promyelocytic leukemia: Induction by vascular endothelial growth factor and inhibition by all-trans retinoic acid. Blood. 97:3919–3924. 2001. View Article : Google Scholar : PubMed/NCBI
29	Vacca A, Ribatti D, Roncali L, Ranieri G, Serio G, Silvestris F and Dammacco F: Bone marrow angiogenesis andprogression in multiple myeloma. Br J Haematol. 87:503–508. 1994. View Article : Google Scholar : PubMed/NCBI
30	Weidner N: Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. Breast Cancer Res Treat. 36:169–180. 1995. View Article : Google Scholar : PubMed/NCBI
31	List AF, Glinsmann-Gibson B, Stadheim C, Meuillet EJ, Bellamy W and Powis G: Vascular endothelial growth factor receptor-1 and receptor-2 initiate a phosphatidylinositide 3-kinase-dependent clonogenic response in acute myeloid leukemia cells. Exp Hematol. 32:526–535. 2004. View Article : Google Scholar : PubMed/NCBI
32	Kuo CJ, Farnebo F, Yu EY, Christofferson R, Swearingen RA, Carter R, von Recum HA, Yuan J, Kamihara J, Flynn E, et al: Comparative evalution of the antitumor activity of antiangiogenic proteins delivered by gene transfer. Proc Natl Acad Sci USA. 98:4605–4610. 2001. View Article : Google Scholar : PubMed/NCBI
33	Kendall RL, Wang G and Thomas KA: Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1 and its heterodimerization with KDR. Biochem Biophys Res Commun. 226:324–328. 1996. View Article : Google Scholar : PubMed/NCBI
34	Lin P, Sankar S, Shan S, Dewhirst MW, Polverini PJ, Quinn TQ and Peters KG: Inhibition of tumor growth by targeting tumor endothelium using a soluble vascular endothelial growth factor receptor. Cell Growth Differ. 9:49–58. 1998.PubMed/NCBI
35	Haouas H: Angiogenesis and acute myeloid leukemia. Hematology. 19:311–323. 2014. View Article : Google Scholar : PubMed/NCBI
36	de Bont ES, Fidler V, Meeuwsen T, Scherpen F, Hählen K and Kamps WA: Vascular endothelial growth factor secretion is an independent prognostic factor for relapse-free survival in pediatric acute myeloid leukemia patients. Clin Cancer Res. 8:2856–2861. 2002.PubMed/NCBI
37	Dias S, Hattori K, Heissig B, Zhu Z, Wu Y, Witte L, Hicklin DJ, Tateno M, Bohlen P, et al: Inhibition of both paracrine and autocrine VEGF/VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias. Proc Natl Acad Sci USA. 98:10857–10862. 2001. View Article : Google Scholar : PubMed/NCBI
38	Rodriguez-Ariza A, Lopez-Pedrera C, Aranda E and Barbarroja N: VEGF targeted therapy in acute myeloid leukemia. Crit Rev Oncol Hematol. 80:241–256. 2011. View Article : Google Scholar : PubMed/NCBI
39	Zhang ZN: Diagnosis and treatment criteria of hematopathy. 2nd. Beijing: Science Press, Beijing; 1998
40	Song G, Li Y and Jiang G: Role of VEGF/VEGFR in the pathogenesis of leukemias and as treatment targets (Review). Oncol Rep. 28:1935–1944. 2012.PubMed/NCBI